Prothena

Prothena is a late-stage clinical company with expertise in protein dysregulation and offers a diverse range of novel investigational therapies for rare peripheral amyloid and neurodegenerative diseases. Committed to developing novel and transformative medicines, Prothena aims to create a better future for those in urgent need of new treatment options. Prothena's diversified portfolio is designed to make a significant impact on rare peripheral amyloid and neurodegenerative diseases.